

X. LIU<sup>1</sup>, J. XU<sup>1</sup>, C.D. HU<sup>2</sup>, Z.L. PAN<sup>1</sup>, Y.C. ZHANG<sup>1</sup>

<sup>1</sup> Department of Rheumatology, Shandong provincial Hospital, Shandong University, Jinan, China

<sup>2</sup> Department of Osteology, Handan central Hospital, Handan, China

E-mail: zhangyuanchao1949@yeah.net, panzhenglun@gmail.com

## THE RELATIONSHIP BETWEEN SNPs IN THE GENES OF TLR SIGNAL TRANSDUCTION PATHWAY DOWNSTREAM ELEMENTS AND RHEUMATOID ARTHRITIS SUSCEPTIBILITY

*Toll-like receptors (TLRs) play an important role in the induction and regulation of the innate immune system or adaptive immune responses. Genetic variations within human TLRs have been reported to be associated with rheumatoid arthritis (RA). This study was conducted to investigate correlation between SNP of downstream mononucleotide in signal transduction of Toll-like receptors and predisposing genes of RA. There was obviously correlative between single nucleotide polymorphism and predisposing genes of RA. G-type of IL-1RAP rs766442 may be protecting genes of RA, while T-type alleles of IL-6R rs11265618 and IL-1RAP rs766442 may be susceptible genes of RA. In conclusion, the studies on the nucleic acid polymorphism in TLRs signal pathway contribute to disclose genes' influence on the attack mechanism of RA, early diagnosis and treatment of RA.*

**Key words:** *Rheumatoid arthritis, Toll like receptors, gene, single nucleotide polymorphism.*

**Introduction.** More and more studies have shown that natural immunity plays an important role in the attack and development of rheumatoid arthritis (RA) [1]. Synovitis is the basic pathological changes of RA, and endogenous antigen is relieved and appears in RA synovial joint spontaneously with the stress, damage and necrosis of cells [2]. Activated antigen presentation cell (APC) can be activated by endogenous antigen, through receptors on the surface. APC can capture and deal with antigens, and gather in synovial lining layer to release inflammatory agents. The inflammatory agents could damage cartilage and bone tissue, resulting in the attack of RA [3]. Toll-like receptors (TLRs) are a group of receptor molecules serving as the medium of natural immune response. There have been clues of TLRs' significance already in the attack of RA [4, 5]. Both TLR2 and TLR4 are important participating molecules [6]. TLR2 can identify and react with many endogenous antigen epitopes, such as heat shock protein (HSP), hyaluronic acid, fibronectin. While TLR4 can identify taxol, fusion protein, heat shock protein 70 (HSP70),

fibronectin, heparin-sulfate proteoglycan fragments, and human fibrinogen [7–9].

TLR signal transduction includes independent and dependent methods of myeloid differentiation protein 88 (MYD88) [10]. Studies on Single Nucleotide Polymorphism (SNP) in links of TLR signal pathway contribute to learning about the hereditary background of RA attack, and accumulate samples for the study on transformation of genes-properties.

Tanaka et al. [11] found that high levels of IL-6 are shown to correlate with disease severity in RA, and contribute to RA onset and pathogenesis. Clinical trial has shown that the monoclonal Ab against the IL-6 receptor (IL-6R) is effective in the treatment of RA, which indicates that the IL-6R may play an important role in the RA pathogenesis [12]. IL-1 is the master mediator of inflammatory responses, and has been implicated in RA. The natural IL-1 receptor antagonist protein (IL-1 RAP) could directly oppose the actions of IL-1 [13]. Sacre et al. [14] discovered that the toll-like receptor adaptor protein MYD88 contributes to the inflammatory and destructive processes in a human model of RA. Zhu et al. [15] hypothesized that the TRAF6 is involved in the pathogenesis of inflammation and osteoclast differentiation, and correlated with the severity in RA. So, the present study intends to adopt the case-control approach, takes *MYD88*, *TRAF6*, *IL-1RAP*, *IL-6*, and *IL-6R* as candidate genes, chooses SNP sites, and inquires into the relations between these genes and RA.

**Materials and methods. Ethics statements.** Written, informed consent was obtained from all patients prior to include into the study. In the case of minors, the consent was provided by the parents. This study was approved by the Ethics committee of the Medical Faculty of Shandong-University Jinan in China. The study protocol adhered to the ethical principles for medical research involving human subjects of the Helsinki Declaration.

© X. LIU, J. XU, C.D. HU, Z.L. PAN, Y.C. ZHANG, 2014

**Study population.** Our study population comprised 350 individuals of Han people in China, including 162 patients with RA, and 188 healthy unrelated individuals as control. The diagnosis of RA patients was based on established guidelines according to RA diagnostic criteria from America Association of Rheumatism (ACR) in 1987 [16]. All patients excluded autoimmune disease, such as Systemic Lupus Erythematosus (SLE), Dermatomyositis or Polymyositis (DM/PM), diabetes, and thyroid diseases. The RA group would be compared with control group whose members are from physical examination department in Shandong Provincial Hospital. The data for cases with RA and controls were shown in Table 1.

**SNP selection.** First, data from the National Center for Biotechnology Information were used to select a total of 9 SNPs. These SNPs could capture most of the genetic diversity across the *TRAF6* and *Myd88* loci (5 SNPs for *TRAF6*, including: rs76834869, rs116937713, rs5030445, rs117428647, rs5030416; 4 SNPs for *MYD88* including: rs7744, rs117598704, rs118081234, rs117074408), with an  $r^2$  threshold set to 0.8 and minor allele frequency (MAF) of 10 %,

according to the information of CHB of the Hap-Map project. Secondly, the SNPs primer or probe design for which had failed were excluded (4 SNPs for *TRAF6*, including: rs76834869, rs116937713, rs117428647, rs5030416; 3 SNPs for *MYD88* including: rs117598704, rs118081234, rs117074408). Finally, 1 SNP for *TRAF6* (rs5030445) were successfully genotyped by SYBR Green 1 real-time PCR [17, 18], and 1 SNP for *MYD88* (rs7744) was gene-typed by TaqMan real-time PCR.

One SNP primer sequence of *IL-1RAP* (rs766442), one SNP primer sequence of *IL-6* (rs6946864) and 2 SNP primer sequences of *IL-6R* (rs11265618, rs4845626) were obtained from Pro. Peter Gergen.

**Table 1.** Data for cases with rheumatoid arthritis and controls

Characteristic	Cases, n	Controls, n
Mean age of disease onset (years)	41.6	43.1
Proportion of females (%)	76.51	74.94
Total subjects available	162	188

**Table 2.** Details of SNPs selected and genotyping sequence of primers/probes

Name	Chromosome position	SNP	Primers/Probes
<i>MYD88</i>	3p22-p21.3	rs7744	CAATGTACAGTATTATACCTCTA[A/G]TGAAGCACAGAGA-GAGGAAGAGAGC
<i>TRAF6</i>	11p12	rs5030445	A GCGGGCGAGGAAGTGAGAAGGGACTGTAT G GCGGGCAGGGCGGCAGGAAGTGAGAAGGGACTGTAC F AGTATTAAAGAAAGTATTAACTGAAGGCTCTACC
<i>IL-1RAP</i>	3q28	rs766442	G GCGGGCAGGGCGGCATCAAGCTCTACATATATTAG T GCGGGCGGCATCAAGCTCTACATATATTAT R GGTGTAACATGAATAACATAAAACTGC
<i>IL-6</i>	7p21	rs6946864	G GCGGGCAGGGCGGGAGACACATGTAAGTCATCATT CTCGG T GCGGGCGGGAGACACATGTAAGTCATCATTCTCGT R GAGATGCTACTACTCTCTATGTCTACTAGAATTG
<i>IL-6R</i>	1q21.3	rs11265618 rs4845626	C GCGGGCAGGGCGGCACATTGGCTGACTTTCTGAAG T GCGGGCGCACTATTGGCTGACTTTCTGAAA F GGTCAATTGGTTTGTCAATTCTACATT F GGATTAGAGCCATCCCTGTTCTCA G GCGGGCAGGGCGGCTTGTCAAGACCTGGACTGTATCC T GCGGGCTTGTCAAGACCTGGACTGTATCA

son. The SNP sites of all these genes are shown in Table 2.

**DNA extraction.** A RelaxGene blood DNA system was used for DNA extraction. From all participants, blood samples were taken, and genomic DNA was isolated by using DNA isolation kit purchased from TIANGEN BIOTECH (Beijing, China) according to the manufacturer's guidelines.

**Genotyping.** Six SNPs (rs5030445, rs7744, rs766442, rs6946864, rs11265618, rs4845626) were genotyped by the method of SYBR Green I real-time PCR. One SNP (rs7744) was genotyped by the method of TaqMan real-time PCR. All SNP analysis were performed using a LightCycler® 480 Instrument system (Roche Diagnostics, Mannheim, Germany) [17, 18]. The total volume of the TaqMan real-time PCR was 10 µl containing 25 ng of genomic DNA, TaqMan Universal PCR Master Mix 5 µl, 0.25 µl

of TaqMan probe (Applied Biosystems Inc.). The PCR comprised a pre-incubation step (95 °C for 10 min), 40 cycles (95 °C for 15 sec, 60 °C for 1 min) and a cooling step (40 °C for 30 sec).

The total volume of the SYBR Green I real-time PCR was 20 µl containing 25 ng of genomic DNA, 10×PCR buffer, 2.5 mM of dNTP Mix, 0.4 µM of forward and reverse primer, 0.8 µM of another primer, SYBR Green I and 5 U/µl Taq HS (above-mentioned obtained from TaKaRa Biotechnology (Dalian), China). The PCR comprised an initial denaturation step (95 °C for 5 min), 31 cycles (denaturation at 95 °C for 10 sec, primer annealing at 60 °C for 15 sec, extension at 72 °C for 15 sec). The melting curve analysis comprised a heating step (95 °C for 5 sec), a step rapidly lowering the temperature to 65 °C and holding for 1 min. The final step was cooling the temperature down to 40 °C for 30 sec.

**Statistical analysis.** Each genetic marker was tested for Hardy-Weinberg equilibrium in the control population [19, 20]. Single-marker allelic tests were performed with Fisher's exact test. All tests were two-tailed, considering P values < 0.05 as significant. Both allelic and genotypic associations between single SNPs and RA susceptibility were analyzed using  $\chi^2$  tests [21].

**Results.** Hardy-Weinberg equilibrium test was satisfied in the observed genotype frequencies for all groups. The genotype and allele distribution for studied polymorphic variants is shown in Table 3 and 4 for the following results.

**Genotype frequency and allele-frequency of MYD88 rs7744.** The results indicated that there were no statistically significant differences in genotype and allele distribution between case and control group ( $P = 0.904$ ,  $P = 0.685$ ).

**Genotype frequency and allele-frequency of TRAF6 rs5030445.** The statistically significant differences were not found in genotype and allele distribution between case and control group ( $P = 0.419$ ,  $P = 0.221$ ).

**Genotype frequency and allele-frequency of IL-1R<sup>A</sup> rs766442.** From the results, we found that GG-homozygote was the rarest type and not found in RA case groups. Through Fisher's test, there were statistically significant differences in genotype and allele distribution between case and control group ( $P = 0.038$ ,  $P = 0.018$ ).

**Genotype frequency and allele-frequency of IL-6 rs6946864.** GT-heterozygote was the most common

Table 3. Distribution of genotype frequency

Gene	Pa-tients (n = = 162)	Cont-rols (n = = 188)	$\chi^2$	p value
<i>MYD88</i> rs7744				
AA	60	74	0.202	0.904
AG	82	92		
GG	20	22		
<i>TRAF6</i> rs5030445				
AA	1	3	1.742	0.419
AG	36	50		
GG	125	135		
<i>IL-1R<sup>A</sup></i> rs766442				
GG	0	3	6.564	0.038
GT	30	51		
TT	132	134		
<i>IL-6</i> rs6946864				
GG	34	53	2.418	0.299
GT	93	98		
TT	35	37		
<i>IL-6R</i> rs11265618				
CC	129	167	5.684	0.058
CT	31	20		
TT	2	1		
<i>IL-6R</i> rs4845626				
GG	131	166	3.802	0.149
GT	30	21		
TT	1	1		

form for these two receptors groups, but the difference among GG-genotypes, TT-genotypes, and GT-genotypes had no statistical significance, so did G/T allele-frequency ( $P = 0.299$ ,  $P = 0.228$ ).

*Genotype frequency and allele-frequency of IL-6R rs11265628 and rs4845626.* For rs11265628, there were no statistically significant differences in genotype and allele distribution between case and control group ( $P = 0.058$ ), and the difference in C/T allele-frequency had statistical significance ( $P = 0.017$ ).

For rs4845626, there were no statistically significant differences in genotype and allele distribution between case and control group ( $P = 0.149$ ,  $P = 0.065$ ).

**Discussion.** *Signal transmission of TLRs.* TLR is defined as a process that the membrane transport receptors identify different ligands through the comprehensive repeating structure of leucine in structural domain outside its cells [22, 23]. TLR signal medium active the signal pathway of inflammation and withering. TLR/IL-1R signal pathway can be realized through two ways: MYD88-dependence and Myd88-independence [24]. The former one can be described as follows: 1) the combination of TIR structural domain between C-terminal of Myd88 and TLR, L-1R, and IL-18R; 2) collect IL-1R associated kinase (IRAK) in the N-terminal death domain; 3) the combination of tumor necrosis factor receptor-associated factor 6 (TARF6),  $\beta$ -type TAK1 and TAB1 and TAB2, get into downstream of signal transmission; 4) I-KB kinase (IKK1-IKK2-IKK) active-KB (NF-kB), or Mitogen-activated protein kinase (MARK) induce conveying of inflammation cells, such as IL-1, IL-6, IL-12, TNF- $\alpha$ , interferon (IFN) and adhesion molecules. Both ways are through activator protein (AP-1) [25–28]. TARF6 is a kind of terminal kinase signal to modify NF-kB and Jun, so the loss of TARF6 may lead to defection of TLR signal, restraining the activation of NF-kB and reducing the inflammation cells nosogenesis [29–31].

Two IL-6 signal transmission ways: Both of traditional receptors' combination and dissolvable receptors' combination need the participation of IL-6R and membrane transport protein gp130 [32, 33]. Traditional signal transmission is the combination of IL-6 and IL-6R in the surface, and this complex cross-link with gp130 into homo-signal. The same result can be realized by sIL-6R, a dissolvable form

of IL-6R, and this is the dissolvable way. These two transmission ways can be achieved by the cascading of Janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase (MARK). IL-6/IL-6R/gp130 complex crosslink with JAK in cytoplasm, and promotes the conveying of Acute Phase Reactants (APA), and finally leads to the over-breed of inflammation cells and the damage of natural autoantibody [34–36].

*The relevance between SNP and RA susceptible gene.* TLR downstream molecules, such as MYD88, TARF6, IL-1RAP, IL-6, IL-6R, were related to the attack of RA. We have chosen 6 SNP sites (rs7744, rs5030445, rs766442, rs6946864, rs11265618, and rs4845626), and found that *IL-1RAP* rs766442 and *IL-6R* rs11265618 allele-frequency makes sense statistically. So this proves that there is obvious relevance between nucleic acid polymorphism of *IL-1RAP*, *IL-6R* and RA susceptible genes. And it also proved that G-type alleles of *IL-1RAP* rs766442 may be protecting genes of RA, while T-type alleles of *IL-6R* rs11265618 and *IL-1RAP* rs766442 may be susceptible genes of RA. Moreover, statistical analysis also showed that there was no relevance

Table 4. Distribution of allele-frequency

Gene	Pa-tients (n = = 162)	Cont-rols (n = = 188)	$\chi^2$	p value
<i>MYD88</i> rs7744				
A	202	240	0.165	0.685
G	122	136		
<i>TRAFF6</i> rs5030445				
A	38	56	1.500	0.221
G	286	320		
<i>IL-1RAP</i> rs766442				
G	30	57	5.567	0.018
T	294	319		
<i>IL-6</i> rs6946864				
G	161	204	1.453	0.228
T	163	172		
<i>IL-6R</i> rs11265618				
C	289	354	5.704	0.017
T	35	22		
<i>IL-6R</i> rs4845626				
G	292	353	3.398	0.065
T	32	23		

between *MYD88* rs7744, *TRAF6*, *IL-6* rs6946864 with RA. But owing to limited number of samples, the result could not be exclusive of the possibility of False Negative Rate (FNR), and the sites with statistical meaning can be caused by False Positive Rate (FPR). So, there is a necessity to expand the number of samples, in that case, we can know the relevance between SNP in the downstream of TLRs signal transduction pathway and RA Susceptible genes.

In conclusion, the studies on the nucleic acid polymorphism in TLRs signal pathway contribute to disclose genes' influence on the attack mechanism of RA, early diagnosis and treatment of RA.

*The study was supported by Shandong Province young scientist in incentive fund (Grant № 2006BS03018) and National Natural Science Foundation of China (Grant № 30801025).*

X. Liu, J. Xu, C.D. Hu, Z.L. Pan, Y.C. Zhang

#### АССОЦИАЦИЯ SNP В ГЕНАХ ЭЛЕМЕНТОВ СИГНАЛЬНЫХ ПУТЕЙ TLR С ПРЕДРАСПОЛОЖЕННОСТЬЮ К РЕВМАТОИДНОМУ АРТРИТУ

Толл-подобные рецепторы (TLRs) играют важную роль в индукции и регуляции врожденной иммунной системы или адаптивных иммунных ответов. Показано, что генетическая изменчивость TLRs человека связана с ревматоидным артритом (РА). Целью настоящей работы было изучение корреляций между одноклеточным полиморфизмом в сигнальной трансдукции TLRs и генами предрасположенности к РА. G-типа IL-1RAP rs766442 могут быть генами, предохраняющими от РА, в то время как аллеи Т-типа IL-6R rs11265618 и IL-1RAP rs766442 могут быть генами чувствительности к РА. Изучение полиморфизма нуклеиновых кислот в сигнальном пути TLRs может внести вклад в выявление участия генов в механизмах приступов РА, раннюю диагностику и лечение РА.

#### REFERENCES

1. Szekanecz Z., Koch A.E. Macrophages and their products in rheumatoid arthritis // Curr. Opin. Rheumatol. – 2007. – **19**. – P. 289–295.
2. Hoffmann J.A., Kaftos F.C., Janeway C.A., Ezekowitz R.A.B. Phylogenetic perspectives in innate immunity // Science. – 1999. – **284**. – P. 1313–1318.
3. Friesen G.S. Evolving concepts of rheumatoid arthritis // Nature. – 2003. – **423**. – P. 356–361.
4. Alieva V.S., Karimov K.Y., Nazarov A.A. et al. Analysis of CTLA4 gene 49A/G polymorphism association with development of allergic rhinitis // Cytology and Genetics. – 2010. – **44**. – P. 140–143.
5. Barton A., Jury F., Eyre S. et al. Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis // Arthritis. Rheum. – 2004. – **50**. – P. 748–752.
6. Izmailova O.V., Shlykova O.A., Bobrova N.O., Kaidashhev I.P. Relationship between the TLR2 and TLR4 gene polymorphisms with a predisposition to certain urogenital infections // Cytology and Genetics. – 2011. – **45**. – P. 225–230.
7. Cohen S., Dadi H., Shaoul E. et al. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase // Lymph Blood. – 1999. – **93**. – P. 2013–2024.
8. Shakiba A.V., Kosmacheva S.M., Kartel N.A., Potapnev M.P. Gene therapy based on human mesenchymal stem cells: strategies and methods // Cytology and Genetics. – 2010. – **44**. – P. 61–65.
9. Sheremet Y.A., Yemets A.I., Azmi A. et al. Effects of tyrosine kinase and phosphatase inhibitors on mitosis progression in synchronized tobacco BY-2 cells // Cytology and Genetics. – 2012. – **46**. – P. 263–271.
10. Joosten L.A., Koenders M.I., Smeets R.L. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88 // J. Immunol. – 2003. – **171**. – P. 6145–6153.
11. Tanaka T., Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases // Int. J. Biol. Sci. – 2012. – **8**. – P. 1227–1236.
12. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor // Rheumatology (Oxford). – 2010. – **49**. – P. 15–24.
13. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family // Annu. Rev. Immunol. – 2009. – **27**. – P. 519–550.
14. Sacre S.M., Andreakos E., Kiriakidis S. et al. The toll-like receptor adaptor protein MYD88 contributes to the inflammatory and destructive processes in a human model of rheumatoid arthritis // Amer. J. Pathol. – 2007. – **170**, № 2. – P. 518–525.
15. Zhu L.J., Zheng D.H., Mo Y.Q. et al. Upregulation of tumor necrosis factor receptor-associated factor 6 correlated with synovitis severity in rheumatoid arthritis // Arthritis. Res. Ther. – 2012. – **14**, № 3. – R133.
16. Arnett F.C., Edworthy S.M., Bloch D.A. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis // Arthritis. Rheum. – 1988. – **31**. – P. 315–324.
17. Audrey C.P., Julia K.P., Glen C. Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves // BioTechniques. – 2003. – **34**. – P. 1068–1072.

18. Wang J., Chuang K., Ahluwalia W. et al. High-throughput SNP genotyping by single-tube PCR with Tm-shift primers // *BioTechniques*. – 2005. – **39**. – P. 885–893.
19. Gabriel S.B., Schaffner S.F., Nguyen H. et al. The structure of haplotype blocks in the human genome // *Science*. – 2002. – **296**. – P. 2225–2229.
20. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps // *Bioinformatics*. – 2005. – **21**. – P. 263–265.
21. Kutsokon N.K. Main trends in the genetic transformation of *Populus* species // *Cytology and Genetics*. – 2011. – **45**. – P. 352–361.
22. Lamb R., Zeggini E., Thomson W. Toll-like receptor 4 gene polymorphisms and susceptibility to juvenile idiopathic arthritis // *Ann. Rheum Dis.* – 2005. – **64**. – P. 767–769.
23. Kutsenko N.L., Izmailova O.V., Vesnina L.E., Kaidashev I.P. Role of toll-like receptor 2 and 4 gene polymorphisms in the development of allergic disease with increased IgE levels // *Cytology and Genetics*. – 2012. – **46**. – P. 379–383.
24. Janssens S., Beyaert R.A. Universal role for MyD88 in TLR/IL-1R-mediated signaling // *Trends Biochem Sci.* – 2009. – **27**. – P. 474–482.
25. Ye H., Arron J.R., Lamothe B. et al. Distinct molecular mechanism for initiating TRAF6 signalling // *Nature*. – 2002. – **418**. – P. 443–447.
26. Kyrychenko A.M., Kovalenko O.G. Genetic basis and functioning of the signal transduction system in plants under the conditions of viral resistance // *Cytology and Genetics*. – 2011. – **45**. – P. 249–258.
27. Greenhill C.J., Rose-John S., Lissila R. et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3 // *J. Immunol.* – 2011. – **186**. – P. 1199–1208.
28. Shablii V.A., Lukash L.L., Lobintseva G.S. The role of some donor-host cell interactions under a microenvironmental influence during regeneration processes // *Cytology and Genetics*. – 2012. – **46**. – P. 180–187.
29. Catherine P., Stephen E., Andrew C., Worthington J., Barton A. Investigation of association between the TRAF family genes and RA susceptibility // *Ann. Rheum. Dis.* – 2007. – **66**. – P. 1322–1326.
30. Huang Q., Ma Y. Increased macrophage activation mediated through Toll-like receptors in rheumatoid arthritis // *Arthritis. Rheum.* – 2007. – **56**. – P. 2192–2201.
31. Kravchenko N.A., Yarmysh N.V. Regulation of the expression of endothelial nitric oxide synthase and dysfunction of vascular endothelium in cardiovascular pathology // *Cytology and Genetics*. – 2008. – **42**. – P. 278–288.
32. Kamimura D., Ishihara K., Hirano T. IL-6 signal transduction and its physiological roles : the signal or chestration model // *Rev. Physiol. Biochem. Pharmacol.* – 2003. – **149**. – P. 1–38.
33. Murakami M., Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective // *Curr. Opin. Rheumatol.* – 2011. – **23**. – P. 273–277.
34. Kravchenko N.A., Yarmysh N.V. Role of PPAFs and their isoforms in metabolic disorders related to insulin resistance and diabetes // *Cytology and Genetics*. – 2011. – **45**. – P. 191–199.
35. Lypez-Mejias R., García-Bermúdez M., González-Juanatey C. et al. Lack of association of IL6R rs2228145 and IL6ST/gp130 rs2228044 gene polymorphisms with cardiovascular disease in patients with rheumatoid arthritis // *Tissue Antigens*. – 2011. – **78**, № 6. – P. 438–441.
36. Arechkov P.A., Kavsan V.M. Chitinase 3-like protein 2 (CHI3L2, YKL-39) activates phosphorylation of extracellular signal-regulated kinases ERK1/ERK2 in human embryonic kidney (HEK293) and human glioblastoma (U87MG) cells // *Cytology and Genetics*. – 2010. – **44**. – P. 1–6.

Received 22.12.12